Delayed release formulations: The latest innovations for enteric coatings, delivery technologies and continuous manufacturing

Overview

The use of enteric coatings is becoming an increasingly popular method by which pharmaceutical and biopharma companies can increase the functional performance and processability of their drug products in an oral solid dosage form.

In this webinar, speakers will review how to increase the flexibility of functional coatings or enable rapid, precise release in particular GIT regions such as the upper small intestine. Specific functionality challenges and solutions for dosage forms including Multiple-Unit-Particulate-Systems (MUPS) and softgels will be reviewed.

Other case studies will explore how to further reduce processing time and cost for delayed release formulations, as well as new developments in continuous manufacturing.

Experts featuring this session

Felix Hofmann
Director Formulation & Application Services EMEA
Evonik Health Care
Vita

Felix Hofmann is director of the Formulation & Application Services EMEA at Evonik Health Care. He is based in Darmstadt, Germany and is responsible for customer-centric and holistic technical support for the health care industry.

Felix began his career in 2002 at Röhm (now Evonik) as a lab technician and in 2015 completed a degree in process engineering specializing in pharmaceutical technology at the University of Applied Science in Bingen, Germany.

Throughout his time at Evonik, Felix has held multiple roles as a senior and principal scientist, handling customer requests, customer projects and process troubleshooting during scale-up and production of coated particles or tablets. He also has experience working on complex customer projects including GMP and HPAPI requirements.

Felix has published several papers and posters on the application of pharmaceutical methacrylates in the formulation of solid dosage forms and is co-inventor of several patents.

Dr. Jessica Müller-Albers
Strategic Marketing Director
Evonik Health Care
Vita

Dr. Jessica Müller-Albers joined Evonik’s Health Care business line in 2010 and is currently working as Strategic Marketing Director for oral solutions.

Before taking over the current position she was group leader for drug delivery where she focused on the development and analytics of new oral and parenteral platform technologies for the pharma and food industry as well as the development of cell culture media.

She held different positions in application service and formulation development of oral excipients and worked for a contract manufacturer where she gained experience in developing solid and semi-solid dosage forms, product transfer, manufacturing of clinical-trial medication, GMP and high potent handling.

She received her degree in pharmacy from the University of Halle/Saale and her Ph.D. from the University of Duesseldorf where she specialized on melt extrusion of poorly soluble drugs.

Moreover, she authored several research papers, book chapters and patents.